Show simple item record

dc.contributor.authorTorvinen-Kiiskinen, S
dc.contributor.authorTolppanen, AM
dc.contributor.authorKoponen, M
dc.contributor.authorTanskanen, A
dc.contributor.authorTiihonen, J
dc.contributor.authorHartikainen, S
dc.contributor.authorTaipale, H
dc.date.accessioned2018-03-21T12:43:57Z
dc.date.available2018-03-21T12:43:57Z
dc.date.issued2018
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6195
dc.description.abstractBackground Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory. Aim To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease. Methods In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression. Results Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37). Conclusions The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.
dc.language.isoEN
dc.publisherWiley-Blackwell
dc.relation.ispartofseriesALIMENTARY PHARMACOLOGY AND THERAPEUTICS
dc.relation.urihttp://dx.doi.org/10.1111/apt.14589
dc.rightsAll rights reserved
dc.titleProton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study
dc.description.versionfinal draft
dc.contributor.departmentSchool of Pharmacy, Activities
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id53067642en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© John Wiley & Sons Ltd
dc.relation.doi10.1111/apt.14589
dc.description.reviewstatuspeerReviewed
dc.relation.issn0269-2813
dc.relation.volume[Epub ahead of print 6 March 2018]
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record